Literature DB >> 28661714

Early Initiation of Amphetamine-Type Stimulants (ATS) Use Associated with Lowered Cognitive Performance among Individuals with Co-Occurring Opioid and ATS Use Disorders in Malaysia.

Weng-Tink Chooi1,2, Norzarina Mohd Zaharim3, Alethea Desrosiers4, Imran Ahmad5, Mohd Azhar Mohd Yasin5, Sharifah Z Syed Jaapar5, Richard S Schottenfeld6, Balasingam K Vicknasingam7, Marek C Chawarski8.   

Abstract

Amphetamine-type stimulants (ATS) use is increasingly prevalent in Malaysia, including among individuals who also use opioids. We evaluated cognitive functioning profiles among individuals with co-occurring opioid and ATS dependence and their lifetime patterns of drug use. Participants (N = 50) enrolling in a clinical trial of buprenorphine/naloxone treatment with or without atomoxetine completed the Raven's Standard Progressive Matrices, Rey-Osterrieth Complex Figure Test, Digit Span, Trail Making and Symbol Digit Substitution tasks. Multidimensional scaling and a K-means cluster analyses were conducted to classify participants into lower versus higher cognitive performance groups. Subsequently, analyses of variance procedures were conducted to evaluate between group differences on drug use history and demographics. Two clusters of individuals with distinct profiles of cognitive performance were identified. The age of ATS use initiation, controlling for the overall duration of drug use, was significantly earlier in the lower than in the higher cognitive performance cluster: 20.9 (95% CI: 18.0-23.8) versus 25.2 (95% CI: 22.4-28.0, p = 0.038). While adverse effects of ATS use on cognitive functioning can be particularly pronounced with younger age, potentially related to greater vulnerability of the developing brain to stimulant and/or neurotoxic effects of these drugs, the current study findings cannot preclude lowered cognitive performance before initiation of ATS use.

Entities:  

Keywords:  Amphetamine-type stimulants; cognitive functioning; dual drug dependence; opioids

Mesh:

Substances:

Year:  2017        PMID: 28661714      PMCID: PMC6218246          DOI: 10.1080/02791072.2017.1342152

Source DB:  PubMed          Journal:  J Psychoactive Drugs        ISSN: 0279-1072


  29 in total

1.  Trail making test, part B as a measure of executive control: validation using a set-switching paradigm.

Authors:  K Arbuthnott; J Frank
Journal:  J Clin Exp Neuropsychol       Date:  2000-08       Impact factor: 2.475

2.  Evaluation of a behavioral measure of risk taking: the Balloon Analogue Risk Task (BART).

Authors:  C W Lejuez; Jennifer P Read; Christopher W Kahler; Jerry B Richards; Susan E Ramsey; Gregory L Stuart; David R Strong; Richard A Brown
Journal:  J Exp Psychol Appl       Date:  2002-06

3.  Early-onset cannabis use and cognitive deficits: what is the nature of the association?

Authors:  Harrison G Pope; Amanda J Gruber; James I Hudson; Geoffrey Cohane; Marilyn A Huestis; Deborah Yurgelun-Todd
Journal:  Drug Alcohol Depend       Date:  2003-04-01       Impact factor: 4.492

4.  Neuropsychological function and delay discounting in methamphetamine-dependent individuals.

Authors:  William F Hoffman; Meredith Moore; Raymond Templin; Bentson McFarland; Robert J Hitzemann; Suzanne H Mitchell
Journal:  Psychopharmacology (Berl)       Date:  2006-08-17       Impact factor: 4.530

5.  Impact of Adolescent Alcohol and Drug Use on Neuropsychological Functioning in Young Adulthood: 10-Year Outcomes.

Authors:  Karen L Hanson; Krista Lisdahl Medina; Claudia B Padula; Susan F Tapert; Sandra A Brown
Journal:  J Child Adolesc Subst Abuse       Date:  2011-01-01

Review 6.  Cannabis and adolescent brain development.

Authors:  Dan I Lubman; Ali Cheetham; Murat Yücel
Journal:  Pharmacol Ther       Date:  2014-11-20       Impact factor: 12.310

7.  Ethnographic assessment of pain coping perceptions.

Authors:  R Moore
Journal:  Psychosom Med       Date:  1990 Mar-Apr       Impact factor: 4.312

8.  Early exposure to stimulant medications and substance-related problems: The role of medical and nonmedical contexts.

Authors:  Sean Esteban McCabe; Phil Veliz; Carol J Boyd
Journal:  Drug Alcohol Depend       Date:  2016-04-26       Impact factor: 4.492

9.  Emerging Drug Use Trends in Kelantan, Malaysia.

Authors:  Alethea Desrosiers; Weng-Tink Chooi; Norzarina Mohd Zaharim; Imran Ahmad; Mohd Azhar Mohd Yasin; Sharifah Z Syed Jaapar; Richard S Schottenfeld; Balasingam Vicknasingam; Marek C Chawarski
Journal:  J Psychoactive Drugs       Date:  2016-05-25

10.  Profiles of cognitive dysfunction in chronic amphetamine and heroin abusers.

Authors:  T J Ornstein; J L Iddon; A M Baldacchino; B J Sahakian; M London; B J Everitt; T W Robbins
Journal:  Neuropsychopharmacology       Date:  2000-08       Impact factor: 7.853

View more
  3 in total

1.  Associations of childhood experiences and methamphetamine use among Akha and Lahu hill tribe youths in northern Thailand: A cross-sectional study.

Authors:  Tawatchai Apidechkul; Chalitar Chomchoei; Pilasinee Wongnuch; Ratipark Tamornpark; Panupong Upala; Fartima Yeemard; Marisa Poomiphak Na Nongkhai; Woottichai Nachaiwieng; Rachanee Sunsern
Journal:  PLoS One       Date:  2020-06-18       Impact factor: 3.240

2.  Atomoxetine for amphetamine-type stimulant dependence during buprenorphine treatment: A randomized controlled trial.

Authors:  Richard S Schottenfeld; Marek C Chawarski; Mehmet Sofuoglu; Weng-Tink Chooi; Norzarina M Zaharim; M Azhar M Yasin; Imran Ahmad; Sharifah Zubaidiah Syed Jaapar; B Kasinather Vicknasingam
Journal:  Drug Alcohol Depend       Date:  2018-03-10       Impact factor: 4.492

3.  Activation of proline biosynthesis is critical to maintain glutamate homeostasis during acute methamphetamine exposure.

Authors:  Bobby Jones; Muthukumar Balasubramaniam; Joseph J Lebowitz; Anne Taylor; Fernando Villalta; Habibeh Khoshbouei; Carrie Grueter; Brad Grueter; Chandravanu Dash; Jui Pandhare
Journal:  Sci Rep       Date:  2021-01-14       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.